Celebrity female hair loss stories have helped bring long-overdue attention to a condition affecting a significant number of women across the UK. Female hair loss is more common than many realise, spanning causes from female pattern hair loss and telogen effluvium to autoimmune and scarring alopecias. Understanding the underlying cause is the essential first step towards effective management. This article covers the most common causes, NHS and private treatment options, lifestyle factors, when to seek medical advice, and where to find trusted support and resources in the UK.

Female Hair Loss: Understanding the Most Common Causes

Female pattern hair loss (androgenetic alopecia) is the most common cause of hair loss in women, but telogen effluvium, alopecia areata, scarring alopecias, thyroid disorders, iron deficiency, and certain medications are also frequently implicated.

Not sure if this is normal? Chat with one of our pharmacists →

Hair loss in women is more prevalent than many people realise, affecting a significant number of women in the UK across all ages, ethnicities, and backgrounds. While high-profile figures and celebrity female hair loss stories have helped bring greater public awareness to the issue, understanding the underlying cause is the essential first step towards effective management.

The most common form is female pattern hair loss (FPHL), also known as androgenetic alopecia. This is a genetically influenced condition in which hair follicles gradually miniaturise in response to androgens, leading to diffuse thinning — typically across the crown and top of the scalp rather than a receding hairline as seen in men. It can begin as early as the late teens or twenties, though it becomes more prevalent after the menopause.

Other frequently encountered causes include:

• Telogen effluvium — a temporary, diffuse shedding triggered by physical or emotional stress, illness, surgery, rapid weight loss, or childbirth. In acute telogen effluvium, shedding typically begins two to three months after the trigger and hair usually regrows within three to six months once the trigger is resolved. Postpartum telogen effluvium commonly begins one to five months after delivery and generally resolves within a year. Chronic telogen effluvium, by definition, persists for more than six months and warrants further investigation.

• Alopecia areata — an autoimmune condition causing patchy hair loss, which can occasionally progress to total scalp or body hair loss.

• Scarring alopecias — including lichen planopilaris and frontal fibrosing alopecia — cause permanent follicular destruction if untreated. These require prompt dermatology referral (see 'When to See a GP', below).

• Traction alopecia — caused by prolonged tension on the hair from tight hairstyles such as braids, weaves, or ponytails.

• Thyroid disorders and iron deficiency anaemia — both common in women and well-recognised contributors to diffuse hair thinning.

• Medications — a number of commonly prescribed drugs can cause or worsen hair loss, including retinoids, anticoagulants (e.g. warfarin, heparin), antithyroid drugs, antiepileptics, lithium, and beta-blockers. If you have recently started a new medicine and notice increased shedding, discuss this with your GP or pharmacist.

Because several of these conditions can present similarly, a thorough clinical assessment is important before any treatment is considered. Information on the range of causes is available from the NHS hair loss page and British Association of Dermatologists (BAD) patient leaflets.

Treatment Options Available on the NHS and Privately

Topical minoxidil is the only MHRA-licensed treatment for female pattern hair loss in the UK; other options — including oral minoxidil, anti-androgens, PRP, and hair transplant surgery — are available privately but require specialist oversight.

Treatment for female hair loss depends entirely on the underlying diagnosis, and options range from licensed topical preparations to more advanced private procedures. It is important to note that not all treatments are available on the NHS, and several remain unlicensed for use in women, meaning they are prescribed off-label at a specialist clinician's discretion.

NHS-available options include:

• Minoxidil (topical) — the only MHRA-licensed topical treatment for hereditary (female pattern) hair loss in the UK. Available over the counter in 2% and 5% formulations, it works by prolonging the anagen (growth) phase of the hair cycle and increasing follicular size. Results typically take three to six months to become apparent, and the treatment must be continued indefinitely to maintain benefit. Topical minoxidil should be avoided during pregnancy and breastfeeding; if you are pregnant, planning a pregnancy, or breastfeeding, discuss this with your GP before use.

• Treatment of underlying conditions — where hair loss is secondary to thyroid dysfunction, iron deficiency, or another systemic cause, addressing that condition via the NHS often leads to natural hair regrowth.

• Alopecia areata management — may include topical or intralesional corticosteroids, available through dermatology referral. Newer systemic options, including JAK inhibitors (e.g. baricitinib, ritlecitinib), have been evaluated for severe alopecia areata; eligibility and NHS commissioning depend on current NICE guidance and local policy — your dermatologist can advise.

Privately available treatments include:

• Oral minoxidil — increasingly used off-label at low doses for hair loss; it is not licensed for hair loss in the UK (in either sex). Evidence is growing but specialist oversight is advisable. Important side effects include hypotension, tachycardia, fluid retention, and hypertrichosis (unwanted hair growth elsewhere). It should not be used during pregnancy or breastfeeding.

• Anti-androgen therapies such as spironolactone or finasteride — occasionally prescribed off-label for FPHL, generally restricted to post-menopausal women or those using reliable contraception, given significant teratogenic risks. Both are contraindicated in pregnancy. Spironolactone may cause hyperkalaemia, menstrual irregularity, and requires blood pressure and electrolyte monitoring. Finasteride may cause sexual dysfunction and mood changes. These medicines should only be initiated and monitored by a specialist.

• Platelet-rich plasma (PRP) therapy — an emerging private procedure. Current evidence is limited and heterogeneous; there is no NICE recommendation for its routine use, and it is not generally available on the NHS.

• Hair transplant surgery — suitable for carefully selected cases of stable FPHL or traction alopecia; NHS availability is very limited. Adequate donor hair supply and disease stability are prerequisites, and thorough pre-operative assessment by a specialist is essential.

If you experience a suspected side effect from any medicine used for hair loss, you can report it to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk).

Experiencing these side effects? Our pharmacists can help you navigate them →

Women should seek assessment from a consultant dermatologist or specialist hair disorders clinic before committing to any private treatment. If considering a trichologist, choose a qualified practitioner registered with a recognised professional body such as the Institute of Trichologists or the Trichological Society; note that trichology is not a regulated medical specialty in the UK.

Lifestyle and Nutritional Factors That Affect Hair Loss in Women

Iron deficiency, low vitamin D, inadequate dietary protein, and chronic psychological stress are the most clinically relevant modifiable factors contributing to hair loss in women.

Whilst genetics and medical conditions are primary drivers of hair loss, lifestyle and nutritional factors can significantly influence hair health and the rate of shedding. Small, evidence-informed changes can support both hair retention and regrowth.

Nutritional deficiencies are among the most modifiable contributors. Key nutrients for hair follicle health include:

• Iron — deficiency is particularly common in women of reproductive age due to menstrual blood loss. Low serum ferritin has been associated with increased hair shedding, though the precise threshold is debated and ferritin levels must be interpreted in clinical context (ferritin is an acute-phase reactant and may be falsely elevated in inflammation). Do not take iron supplements unless a deficiency has been confirmed by a blood test and is being monitored by a clinician, as excess iron can be harmful.

• Vitamin D — low levels have been linked to alopecia areata and telogen effluvium, though the causal relationship requires further research.

• Zinc, biotin, and B vitamins — deficiencies are less common in those eating a balanced diet, but may be relevant in women following highly restrictive diets or with malabsorption conditions. Important: the MHRA has advised that high-dose biotin (vitamin B7) supplements can interfere with a range of laboratory tests, including thyroid function tests and troponin assays, potentially producing misleading results. If you are taking biotin supplements, inform your GP and consider pausing them for at least two days before any blood tests, as advised by your clinician.

• Protein — adequate dietary protein is essential, as hair is composed primarily of keratin. Very low-calorie or crash diets are a well-recognised trigger for telogen effluvium.

Beyond nutrition, chronic psychological stress is a significant and often underappreciated trigger for diffuse hair shedding. Stress can disrupt the hair growth cycle. Evidence-based stress management strategies — including mindfulness, regular physical activity, and adequate sleep — support overall wellbeing and may indirectly benefit hair health, though the direct effect on hair loss should not be overstated.

Hairstyling practices also warrant consideration. Frequent use of heat tools, chemical treatments, and tight styling can cause mechanical and thermal damage to the hair shaft and, over time, contribute to traction alopecia. Gentle handling, wide-toothed combs, and heat protectants are simple protective measures.

When to See a GP About Female Hair Loss

See your GP promptly if you notice sudden or patchy hair loss, scalp symptoms suggesting scarring alopecia, signs of an underlying systemic condition, or no improvement after three to six months of minoxidil use.

Many women delay seeking medical advice about hair loss, often attributing it to normal ageing or stress. However, timely assessment is important — both to identify any treatable underlying cause and to begin appropriate management before significant follicular damage occurs. Celebrity female hair loss disclosures have helped normalise the conversation, but professional evaluation remains essential.

You should make an appointment with your GP if you notice:

• Sudden or rapid hair loss over a period of weeks rather than gradual thinning

• Patchy hair loss, bald spots, or loss of eyebrows and eyelashes

• Scalp symptoms such as redness, scaling, itching, or pain — particularly if follicular openings appear absent or there is scarring, which may suggest a scarring alopecia requiring urgent dermatology referral

• Hair loss accompanied by other symptoms such as fatigue, weight changes, irregular periods, or skin changes — which may suggest an underlying systemic condition

• Signs of hyperandrogenism such as hirsutism (excess facial or body hair) or severe acne, which may indicate polycystic ovary syndrome (PCOS) or another endocrine condition requiring targeted investigation

• Hair loss that is causing significant psychological distress or affecting quality of life

• No improvement after three to six months of over-the-counter minoxidil use

• You are pregnant, planning a pregnancy, or breastfeeding and wish to discuss treatment options

At the appointment, your GP will typically take a detailed history, examine the scalp, and arrange blood tests to exclude common medical causes. These usually include a full blood count, serum ferritin, and thyroid function tests; hormonal profiles may be requested where clinically indicated. If you are taking high-dose biotin supplements, inform your GP before blood tests are taken, as these can interfere with results.

Depending on findings, referral to a consultant dermatologist or specialist hair disorders clinic may be appropriate. Scarring alopecias in particular require prompt specialist assessment to prevent irreversible follicular loss.

A holistic approach to hair loss — addressing both physical and psychological aspects — is consistent with good clinical practice. Psychological support, including talking therapies, may be beneficial for women experiencing significant distress; your GP can refer you to NHS Talking Therapies (formerly IAPT) or other appropriate services. Women should feel empowered to raise concerns with their GP and ask for onward referral if needed. Early intervention generally yields better outcomes.

Support and Resources for Women Experiencing Hair Loss in the UK

Alopecia UK, the British Association of Dermatologists, and NHS Talking Therapies are key UK resources offering clinical information, peer support, and psychological help for women affected by hair loss.

Hair loss can have a profound impact on self-esteem, body image, and mental health, and women should know that they are not alone and that support is available. The growing visibility of celebrity female hair loss stories has contributed to reducing stigma, but practical, accessible support remains vital for those navigating the condition day to day.

NHS and clinical support includes referral to a consultant dermatologist or specialist hair disorders clinic. Psychological support — including cognitive behavioural therapy (CBT) — may be available through NHS Talking Therapies (formerly known as IAPT; refer via your GP or self-refer at nhs.uk/mental-health/talking-therapies-medicine-treatments/talking-therapies-and-counselling/nhs-talking-therapies) for women experiencing significant distress related to hair loss.

Charitable and peer support organisations in the UK include:

• Alopecia UK (alopecia.org.uk) — a leading charity offering information, peer support groups, and an online community for those with all forms of alopecia.

• The Trichological Society and the Institute of Trichologists — provide directories of qualified trichologists and evidence-based information for patients. Note that trichology is not a regulated medical specialty; for medical diagnosis and treatment, a consultant dermatologist is the appropriate specialist.

• British Association of Dermatologists (BAD) (bad.org.uk) — provides authoritative, patient-friendly leaflets on female pattern hair loss, telogen effluvium, alopecia areata, and scarring alopecias.

• Macmillan Cancer Support — for women experiencing hair loss as a result of chemotherapy, Macmillan offers practical guidance on scalp cooling, wigs, and emotional support.

Practical considerations such as wigs and hairpieces may be available on the NHS for women whose hair loss results from a medical condition or its treatment, including chemotherapy. Eligibility and provision vary by NHS trust, and charges may apply in England. Full details, including how to access support, are available on the NHS wigs and fabric supports page (nhs.uk).

Online communities and forums — when moderated responsibly — can provide valuable peer connection. However, women should be cautious about unregulated advice or products promoted on social media. Always verify treatment claims against reputable sources such as the NHS website, NICE guidelines, BAD patient leaflets, or the MHRA. If you suspect a side effect from any medicine or supplement, report it via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk). Seeking support is a sign of strength, and effective help is available.

Frequently Asked Questions